Alex Goldberg

NASDAQ Decliners Watch List: Hologic Inc. (NASDAQ:HOLX) and PDL BioPharma, Inc. (NASDAQ:PDLI) Added to Equity Profile Report's NASDAQ Decliners Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 06/14/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Hologic Inc. (NASDAQ:HOLX) and PDL BioPharma, Inc. (NASDAQ:PDLI).

Hologic Inc. (NASDAQ:HOLX) a company that develops, manufactures, and supplies diagnostics, medical imaging systems, and surgical products for women closed down in its previous session (-1.66%) on 2,077,845 shares traded. Hologic Inc. (NASDAQ:HOLX) is currently down (-11.52%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Hologic Inc. (NASDAQ:HOLX)

PDL BioPharma, Inc. (NASDAQ:PDLI) a company that engages in intellectual property asset management and patent portfolio and related assets investment activities closed down in its previous session (-0.76%) on 1,425,878 shares traded after PDL BIOPHARMA, INC. Filed SEC form 8-K, Other Events, Financial Statements and Exhibits. PDL BioPharma, Inc. (NASDAQ:PDLI) is currently down (-8.02%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about PDL BioPharma, Inc. (NASDAQ:PDLI)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com